3Ignaut DA, Venekamp WJ. HumaPen Memoir: a novel insulin injecting pen with a dose-memory feature[J]. Expert Rev Med Devices, 2007,4 (6) : 793-802.
4Cherrington AD, Neal DW, Edgerton DS, et al. Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection[J]. Diabetes, 2004,53 (4): 877-881.
5Skyler JS,Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects:a 6-month, randomized, comparative trial [J]. Diabetes Care,2005,28(7) : 1630-1635.
6Hollander PA,Blonde L,Rowe R,et al. Efficacy and safety of inhaled insulin (exubera)compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6 month, randomized, comparative trial [J]. Diabetes Care, 2004, 27 (10):2356-2362.
7Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a &month, randomized, comparative trial [J]. Diabetes Care, 2004,27(11) :2622-2627.
8Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus inject able insulin in patients with type 1 diabetes[J]. Diabetologia, 2006,49(5) :891-899.
9Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes[J]. Diabetes Care, 2004,27 (1) : 162-167.
10Rave KM, Nosek L, de la Pena A, et al. Dose response of inhaled dry power insulin and dose equivalence to subcutane ous insulin lispro [J]. Diabetes Care, 2005, 28 (10): 2400-2405.
二级参考文献20
1Michele Giugliano,Marco Bove,Massimo Grattarola.Insulin Release at Molecular Lever:. Metabolic-Electrophysiological Modeling of the Pancreatic Beta-Cells. IEEE Transactions on Biomedical En gineering, 2000,47(5)
2JACOB JAREMKO, BSC OTTO RORSTAD, MD PHD.Advances Toward the Implantable Artificial Pancreas for Treatment of Dia betes. Diabetes Care, 1998,21(3):444-450 .
5S.Hirotani. H,Ohgawara T,Akaike et al. Miyazaki:A Bio-Artifical Endocrine Pancreas for the Treatment of Diabetes. Transplantation Proceedings, 1998,30:485-489
6Shichiri,-M, Sakakida,-M, Nishida,-K, el al.simplified glucose sensors:long-term clinical application of wearable artificial en docrine pancreas. Artif-Organs, 1998,22(1): 32-42.
7Selam-JL,Micossi-P,Dunn-FL,et al. Clinical trial of programmable implantable insulin pump for type I diabetes. Diabetes-Care,1992,15(7):877-85
8曾淑范.胰岛素分子生物学与糖尿病[M].天津:天津科技翻译出版公司,1995.202-207.
9Durra C, Curran MP. Inhaled human insulin ( Exubera ) : a review of its use in adult patients with diabetes mellitus. Drugs,2006, 66:1013-1032.
10Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamica of inhaled insulin. Clin Pharmacokinet, 2004,43 : 781-801.
5DESA1 S D, BLANCHARD J. In vitro evaluation of pluronic F127-based controlled release ocular delivery systems for pilocarpine [ J]. J Pharm Sci, 1998,87:226 - 230.
6LEDERER C M Jr, HAROLD R E. Drop size of comer cialglaucoma medications [J]. Am J Ophthalmol, 1986, 101 (6) :691 -692.
